Publications on Tunneling Nanotubes (TNTs)

Our abstracts on Tunneling Nanotubes (TNTs)

Cancer biology and therapeutics

Book chapters

  • E Shillitoe and E Lou. Oncolytic viruses. In: Cancer and Gene Therapy. Editor: Paul Hermonat. Transworld Research Network, ISBN 81-7895-25201. pp. 67-84. 2007.
  • E Lou and S Subramanian. Tunneling Nanotubes: Intercellular conduits for direct cell-to-cell communication in cancer. In Intercellular Communication in Cancer. Springer Publishing, November 2015.

Clinical research publications

  • E Lou, KP Peters, AL Sumrall, A Desjardins, DA Reardon, ES Lipp, JE Herndon II, A Coan, L Bailey, S Turner, HS Friedman, JJ Vredenburgh. Phase II trial of upfront Bevacizumab and Temozolomide for unresectable or multifocal glioblastoma. Cancer Medicine 2(2): 185-95, April 2013; Epub January 24, 2013.
  • D Reardon, JE Herndon II, KB Peters, A Desjardins, A Coan, E Lou, AL Sumrall, S Turner, ES Lipp, S Sathomsumetee, JN Rich, JH Sampson, AH Friedman, ST Boulton, DD Bigner, HS Friedman, JJ Vredenburgh. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer, October 4 2012. doi: 10.1038/bjc.2012.415.
  • E Lou, A Sumrall, S Turner, K Peters, A Desjardins, JJ Vredenburgh, R McLendon, JE Herndon II, F McSherry, J Norfleet, HS Friedman, DA Reardon. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. Journal of Neurooncology, 2012 August;109(1):63-70. Epub 2012 Apr 26.
  • DA Reardon, JE Herndon 2nd, K Peters, A Desjardins, A Coan, E Lou, A Sumrall, S Turner, S Sathornsumetee, JN Rich, S Boulton, ES Lipp, HS Friedman, JJ Vredenburgh. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. Journal of Neurooncology 107(1): 213-21, March 2012 (Epub ahead of print October 14 2011).
  • E Lou, S Turner, A Sumrall, D Reardon, A Desjardins, KB Peters, JH Sampson, HS Friedman, J Vredenburgh. Bevacizumab-induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient with Glioblastoma. Journal of Clinical Oncology Vol. 29(28): e739-e742, October 1 2011.
  • E Lou, J Marshall, M Aklilu, D Cole, D Chang,, and M Morse. A Phase II Study of Active Immunotherapy with PANVACTM or Autologous, Cultured Dendritic Cells Infected with PANVACTM after Complete Resection of Hepatic Metastases of Colorectal Carcinoma. Invited review, Clinical Colorectal Cancer, 5(5): 368-71, January 2006.

Review articles

  • E Lou. Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research. Annals of Medicine, 36(1): 2-8, January 2004.
  • E Lou. Oncolytic herpes viruses as a potential mechanism for cancer therapy. Acta Oncologica, 42(7): 660-671, November 2003.
  • E Lou. A Long Trail. Science-Next Wave online, Feature on MD-PhD training.
  • E Lou. Xenotransplantation and the risk of transmission of porcine endogenous retroviruses. Clinical Microbiology Newsletter, 24(23): 175-179, December 1, 2002.
  • E Lou. Bone Morphogenetic Proteins: An Overview of Therapeutic Applications. Orthopedics, 24(5): 504-509, CME quiz 510-511, May 2001.